Camupepimut shows early disease free survival signal in resected KRAS mutated pancreatic cancer

Prof Eileen O'Reilly speaks to ecancer about the phase II AMPLIFY-7P trial.

This trial evaluates camupepimut (ELI-002 7P), an investigational immunotherapy targeting mutant KRAS, in patients with resected stage I–III KRAS-mutated pancreatic ductal adenocarcinoma (PDAC).

Prof O'Reilly says that although the primary disease-free survival (DFS) endpoint was not met, camupepimut showed a numerical advantage in 6-month DFS compared with observation (75.7% versus 61.7%).

Patients with mutant KRAS-specific T-cell responses also had significantly longer DFS.

The findings highlight the potential role of targeted immunotherapy in reducing recurrence risk following curative-intent treatment, warranting further investigation.